Bortezomib

Those suited to the allowable route s ; of administration. Statement s ; to the effect of: A factor in the maintenance of good health IOM 2006. 1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 156571. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 260917. Richardson PG, Jagannath S, Schlossman RL, et al. A multicenter, randomized phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with Dexamethasone for the treatment of relapsed and refractory multiple myeloma abstract ; . Blood. 2002; 100: 104a. Palumbo A, Bringhen S, Musto P, et al. Oral melphalan, and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006; 367: 825-31. Facon T, Mary JY, Hulin C, et al. Major Superiority of Melphalan - Prednisone MP ; + Thalidomide THAL ; over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma abstract ; . Blood. 2005; 106: 230a. Mateos MV, Hernandez M, Mediavilla JD, et al. A Phase I II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone V-MP ; in Elderly Untreated Multiple Myeloma MM ; Patients abstract ; . Blood. 2005; 106: 232a. Dimopoulos M, Spencer A, Attal M, et al. Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma MM ; : Results of a Phase 3 Study MM-010 ; abstract ; . Blood.2005; 106: 6a. 8. Palumbo A, Falco P, Musto P, et al. Oral Revlimid Plus Melphalan and Prednisone R-MP ; for Newly Diagnosed Multiple Myeloma abstract ; . Blood. 2005; 106: 231a. Patients were treated with i.v. bortezomib from 0.13 to 2.0 mg m2, once weekly for 4 weeks every 5 weeks. Thirty-one of 53 patients enrolled completed at least two cycles of bortezomib; 39 patients completed at least one cycle of treatment. In addition to monitoring toxicity, measurable disease response, serum IL-6, and prostatespecific antigen levels, 20S proteasome inhibition was measured in patients pre- and postdosing to examine possible correlations among bortezomib dose, proteasome inhibition, toxicity, and tumor response. The most frequent adverse events on this schedule included diarrhea, fatigue weakness, constipation, nausea, vomiting, other gastrointestinal complaints, hypotension, dizziness, hypertension, and neuropathy. The dose-limiting toxicities included grade 3 diarrhea and grade 3 postural hypotension at the 2.0 mg m2 dose level Table 3 ; . In studies using a twice-weekly treatment regimen, peripheral sensory neuropathy was frequent; however, neuropathy was less common on the once-weekly schedule, occurring in 8% of patients 2% grade 3 ; , although many patients had received potentially neurotoxic drugs previously. Dose-related inhibition of whole-blood proteasome activity was observed, with most toxicity diarrhea, hypotension, and fatigue ; seen at doses 1.45 mg m2 ; that yielded 70% proteasome inhibition 1 h after treatment. The maximum tolerated dose in this schedule was 1.6 mg m2. Antitumor responses measurable disease and prostatespecific antigen responses ; were seen in 2 and 3 patients, respectively, among the 48 patients with AIPC. One of the 2 objective partial responses and all 3 of the prostate-specific antigen responses occurred at doses resulting in average 1-h postbortezomib whole-blood 20S proteasome inhibition of 70%, which also is associated with doselimiting toxicity, suggesting a narrow therapeutic index with monotherapy in prostate carcinoma in this study. Proteasome inhibition was associated with decline in serum IL-6 levels, suggesting that bortezomib may be affecting NF B signaling and autocrine paracrine mechanisms in vivo. Additional studies of bortezomib in patients with prostate cancer are warranted, and we are focusing on combination treatments with cytotoxic agents that may reverse resistance to chemotherapy. Two additional single-agent Phase I trials of bortezomib, one in solid tumors 19 ; and another in hematological malignancies 16 ; , have been published that support additional studies of this agent for the treatment of cancer. Whereas these studies were not designed to assess efficacy, clinically significant responses were observed. Bortezomib has demonstrated significant biological activity in a Phase II study of relapsed and refractory myeloma patients 108 ; and has received United States Food and Drug Administration approval for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies and have progressed on their last. Abnormalities of glucose homeostasis, primarily insulin resistance, are common in patients on antiretroviral therapy, with a greater frequency of abnormalities observed in patients receiving PIs. The mechanisms of these abnormalities remain largely undefined. Management includes encouraging weight loss for overweight individuals. Treatment with insulin-sensitizing agents may be beneficial; diabetes treatment guidelines should be followed in HIV-infected individuals. Recent findings in this area include an association of hyperinsulinemia with the dorsocervical fat deposit termed "buffalo hump" in HIV-infected patients Mallon et al, J Acquir Immune Defic Syndr, 2005 ; . This finding indicates that patients with buffalo hump should be closely followed for insulin resistance and diabetes. It also suggests that caution should be exercised when using human growth hormone for treating buffalo hump, since growth hormone is associated with hyperinsulinemia.
GREECE Antisel A. Selidis Bros. S. A. ; Tel: 30 210 779 Fax: 30 210 771 Email: aaidini antisel.gr HUNGARY Per-Form Hungaria KFT Tel: 361 251 1116-2163-0230 Fax: 361 251 1461 Email: liptak klos per-form.hu ICELAND Groco ehf Tel: 354 568 8533 Fax: 354 568 0304 Email: eirikur groco LATVIA Adrona Sia Tel: 371 755 1894 Fax: 371 755 1976 Email: agris adrona.lv LITHUANIA Linea Libera Tel: 370 5 2729 Fax: 370 5 2729 Email: paulius.jurgutis mega i.lt MALTA Technoline Ltd Tel: 00356 21 344 Fax: 00356 21 343 Email: sdebono technoline-mt NORWAY Tel: 800 18 854 Fax: 800 18 855 Email: cc.norway perkinelmer POLAND PerkinElmer Polska Sp. z o.o. Tel: 48 22 607 Fax: 48 22 607 Email: andrzej.lechotycki perkinelmer PORTUGAL ILC Instrumentos de Laboratrio e Cientficos Lda Tel: 351 21 782 Fax: 351 21 782 Email: ilc ilc.pt REPUBLIC OF IRELAND AND NORTHERN IRELAND Foss Ireland Tel: 353 1 250 Fax: 353 1 250 Email: aoreilly foss.ie ROMANIA SC Cromatec Plus Srl Tel: 40 21 316 Fax: 40 21 316 Email: office cromatec SLOVAKIA Medic Labor S.r.o Tel: 421 48 4155008 Fax: 421 48 4155007 Email: slaszlo medic-labor.sk SLOVENIA Omega d.o.o Tel: 386 1 427 Fax: 386 1 427 Email: omega omega.si SWEDEN Tel: 0200 - 88 75 20 Fax: 0200 - 88 75 21 Email: cc.sweden perkinelmer SWITZERLAND Tel: 0800000015 Fax: 0800000016 Email: cc.switzerland perkinelmer TURKEY Tetra Teknolojik Sistemler Ltd Tel: 90 212 Fax: 90 212 Email: istanbul tetratek .tr UNITED KINGDOM Tel: 0800-89 60 46 Fax: 0800-89 17 14 Email: cc perkinelmer YUGOSLAVIA Interlab d.o.o Tel: 381 11 2404 Fax: 381 11 2404 Email: interlab eunet.yu GAZA STRIP IRAQ JORDAN LEBANON LIBYA NEUTRAL ZONE IQ SA ; SYRIA WEST BANK PerkinElmer Egypt Limited Tel: 20 2 391 Fax: 20 2 392 Email: sadekna ie-eg EGYPT Optima Scientific Egypt HTDS Tel: 202 418 8606 Fax: 202 290 5307 Email: sadekna ie-eg ISRAEL Saifan Precision Instruments Ltd Tel: 972-3-7565000 Fax: 972-3-7565007 Email: john saifan.co.il KUWAIT Bader Sultan & Bros Co. W.L.L. Tel: 965 43325555 Ext. 326 ; Fax: 965 4334217 Email: hisham sultan .kw OMAN Business International Group L.L.C. Tel: 968 248 14752 Fax: 968 248 13924 Email: bigllc omantel .om PALESTINE Techno-Line Tel: 972-2-6560077 Fax: 972-2-6568796 Email: a.imam techno-line QATAR UNITED ARAB EMIRATES Emphor FZCO Tel: 971 4 883 Fax: 971 4 883 Email: nilesh emphor SAUDI ARABIA Abdulrehman AlgoSaibi G.T.B. Tel: 966 672 0888 Fax: 966 672 5664 Email: ielhajj algosaibi-gtb YEMEN Alfalah Trading Tel: 967 234 5073 Fax: 967 234 0504 Email: direct alfalahye. After exposure to bortezomib or HDAC inhibitors administered individually. However, sequential exposure resulted in a very pronounced increase in apoptosis in these cells, analogous to results obtained with continuously cultured myeloma cell lines. Interestingly, the CD138 bone marrow cell population was largely unaffected by exposure to bortezomib and HDAC inhibitors, alone or in combination. These findings indicate that sequential exposure to bortezomib and HDAC inhibitors leads to a marked increase in apoptosis in at least some primary patient-derived myeloma cells. They also raise the possibility that the selective lethality proteasome inhibitors exhibit toward neoplastic cells 36 ; may extend to combinations involving HDAC inhibitors and bosentan. 21. Kasuga, C., T. Ebata, N. Kayagaki, H. Yagita, M. Hishii, H. Arai, K. Sato, and K. Okumura. 2004. Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand TRAIL ; by NF- B inhibitors. Cancer Sci. 95: 840 844. Leverkus, M., M. Neumann, T. Mengling, C. T. Rauch, E. B. Brocker, P. H. Krammer, and H. Walczak. 2000. Regulation of tumor necrosis factorrelated apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 60: 553559. 23. Fernandez, V., P. Jares, S. Bea, I. Salaverria, E. Guino, S. de Sanjose, D. Colomer, G. Ott, E. Montserrat, and E. Campo. 2004. Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89: 13221331. 24. Griffith, T. S., J. M. Fialkov, D. L. Scott, T. Azuhata, R. D. Williams, N. R. Wall, D. C. Altieri, and A. D. Sandler. 2002. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 62: 30933099. 25. Ng, C. P., A. Zisman, and B. Bonavida. 2002. Synergy is achieved by complementation with Apo2L TRAIL and actinomycin D in Apo2L TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53: 286 299. Chen, X., H. Thakkar, F. Tyan, S. Gim, H. Robinson, C. Lee, S. K. Pandey, C. Nwokorie, N. Onwudiwe, and R. K. Srivastava. 2001. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073 6083. Ricci, M. S., Z. Jin, M. Dews, D. Yu, A. Thomas-Tikhonenko, D. T. Dicker, and W. S. El-Deiry. 2004. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. 24: 8541 8555. Aza-Blanc, P., C. L. Cooper, K. Wagner, S. Batalov, Q. L. Deveraux, and M. P. Cooke. 2003. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell. 12: 627 637. Kelly, M. M., B. D. Hoel, and C. Voelkel-Johnson. 2002. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol. Ther. 1: 520 527. Hietakangas, V., M. Poukkula, K. M. Heiskanen, J. T. Karvinen, L. Sistonen, and J. E. Eriksson. 2003. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol. Cell Biol. 23: 1278 1291. Higuchi, H., J. H. Yoon, A. Grambihler, N. Werneburg, S. F. Bronk, and G. J. Gores. 2003. Bile acids stimulate cFLIP phosphorylation enhancing TRAILmediated apoptosis. J. Biol. Chem. 278: 454 461. Pham, L. V., A. T. Tamayo, L. C. Yoshimura, P. Lo, and R. J. Ford. 2003. Inhibition of constitutive NF- B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 171: 88 95. Kim, Y., N. Suh, M. Sporn, and J. C. Reed. 2002. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277: 22320 22329. Sayers, T. J., and W. J. Murphy. 2006. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand Apo2L TRAIL ; for cancer therapy. Cancer Immunol. Immunother. 55: 76 84. An, J., Y. P. Sun, J. Adams, M. Fisher, A. Belldegrun, and M. B. Rettig. 2003. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor TNF ; , and TNF-related apoptosis-inducing ligand in prostate cancer. Clin. Cancer Res. 9: 4537 4545. Burke, J. R., M. A. Pattoli, K. R. Gregor, P. J. Brassil, J. F. MacMaster, K. W. McIntyre, X. Yang, V. S. Iotzova, W. Clarke, J. Strnad, et al. 2003. BMS-345541 is a highly selective inhibitor of I B kinase that binds at an allosteric site of the enzyme and blocks NF- B-dependent transcription in mice. J. Biol. Chem. 278: 1450 1456. Kucharczak, J., M. J. Simmons, Y. Fan, and C. Gelinas. 2003. To be, or not to be: NF- B is the answerrole of Rel NF- B in the regulation of apoptosis. Oncogene 22: 8961 8982. MacFarlane, M., S. L. Kohlhaas, M. J. Sutcliffe, M. J. Dyer, and G. M. Cohen. 2005. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65: 1126511270. 39. MacFarlane, M., S. Inoue, S. L. Kohlhaas, A. Majid, N. Harper, D. B. Kennedy, M. J. Dyer, and G. M. Cohen. 2005. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 12: 773782. 40. Yang, J., K. I. Amiri, J. R. Burke, J. A. Schmid, and A. Richmond. 2006. BMS345541 targets inhibitor of B kinase and induces apoptosis in melanoma: involvement of nuclear factor B and mitochondria pathways. Clin. Cancer Res. 12: 950 960. Net revenues amounted to SEK 199.8 M 248.2 ; . The quarter showed a negative result of SEK -22.5 M 5.6 ; , which is equivalent to earnings per share of SEK -0.49 0.13 ; . This is in line with previously communicated outlook and is mainly due to lower ReFacto deliveries in the third quarter as a consequence of high delivery levels in the first half year as well as lower revenues from contract development. Cash flow from operations improved in the third quarter and increased by SEK 25 M and amounted to SEK -46.4 M. Biovitrum obtained the first approval for initiation of a clinical phase II trial of KiobrinaTM in Italy and France. An application to start the first clinical phase I II study of FIXfc in hemophilia B patients was submitted to the US Food and Drug Administration, FDA. Marketing activities started for the hemophilia B product BeneFIX in the Nordic region. Biovitrum signed an agreement with the Danish pharmaceutical company Lundbeck. Under the agreement, Lundbeck has licensed certain non-exclusive patent rights related to the 5-HT area and in fields outside Biovitrum's primary therapeutic area interests and botox. Melanoma is the most aggressive form of skin cancer and advanced stages are invariably resistant to conventional therapeutic agents. Using bortezomib as a prototypic proteasome inhibitor, we have identified a novel and critical role of the proteasome in the maintenance of the malignant phenotype of melanoma cells that could have direct translational implications. Thus, melanoma cells from early, intermediate, and late stages of the disease could not sustain proteasome inhibition and underwent an effective activation of caspase-dependent and -independent death programs. This effect was tumor cell selective, because under similar conditions, normal melanocytes remained viable. Intriguingly, and despite of interfering with a cellular machinery in charge of controlling the half-life of the vast majority of cellular proteins, bortezomib did not promote a generalized disruption of melanoma-associated survival factors including NF-KB, Bcl-2, Bcl-xL, XIAP, TRAF-2, or FLIP ; . Instead, we identified a dramatic induction in vitro and in vivo of the BH3-only protein Noxa in melanoma cells but not in normal melanocytes ; in response to proteasome inhibition. RNA interference validated a critical role of Noxa for the cytotoxic effect of bortezomib. Notably, the proteasome-dependent regulation of Noxa was found to extend to other tumor types, and it could not be recapitulated by standard chemotherapeutic drugs. In summary, our results revealed Noxa as a new biomarker to gauge the efficacy of bortezomib specifically in tumor cells, and provide a new strategy to overcome tumor chemoresistance. Cancer Res 2005; 65 14 ; : 6294-304. For short-term in vitro microcytotoxicity assays, rbc-depleted splenocytes, harvested 3 days after bortezomib treatment, were cultured in vitro for 96 h at the same conditions described above for elispot assays, and assayed in a standard 4-h chromium release test as we have previously described 21 and bronchial. Therapy 109 ; . Additional trials studying bortezomib as monotherapy and in combination with other antineoplastic agents are ongoing in multiple myeloma and in other types of malignancy. Most are Phase I exploratory studies, and promising results are beginning to emerge Table 4; Refs. 108, 110 115 ; . A Phase III randomized trial of the treatment of multiple myeloma with bortezomib monotherapy versus dexamethasone was halted recently at the interim analysis because of significantly greater efficacy in the bortezomib arm. Study analyses are ongoing. Conclusion The proteasome plays a central role in regulation of the cell cycle, proliferation, cell death, angiogenesis, metastasis, and resistance to chemotherapy and radiation therapy. Results from cell culture systems, animal tumor models, and early clinical studies suggest that proteasome inhibition represents a new therapy target for human cancers, including AIPC. Bortezomib is the first agent of this novel class to enter clinical trials, and antitumor activity has been reported from preclinical investigations in a variety of tumor models. In some diseases, like multiple myeloma, antitumor activity is significant even as a single agent, and bortezomib has been approved for the treatment of patients with multiple myeloma who have received at least two prior therapies and have demonstrated disease progression on their last therapy. In AIPC, bortezomib seems to have weak single agent antitumor activity. Preclinical models suggest synergy with some conventional chemotherapeutic agents with activity against AIPC. Additional studies are under way to additionally examine the role of bortezomib in combination with chemotherapy in AIPC as well as other cancers in which the proteasome has an active role in transformation, chemoresistance, and disease progression. References.
Ence 4 ; . These prior studies have also highlighted the diverse vasoactive properties of the 2 peptides among different species and even among the different vascular beds of the same organ of a single species. Moreover, although the 2 peptides often have the same vasoactive effect in a particular bed, at times these effects may be different and may be differentially affected by pathophysiological states.5 The results of the present study extend these prior studies, demonstrating that both insulin and IGF-1 are coronary vasorelaxants of porcine coronary arteries and arterioles in vitro. Furthermore, in contrast to the similar effects exerted by the 2 peptides on epicardial vessels, IGF-1 was more effective in causing vasorelaxation of porcine coronary arterioles. The peptides belonging to the IGF family interact with specific receptors designated as type 1 and 2 IGF receptors, as well as with the insulin receptor.1 The type 1 IGF receptor binds IGF-1 with high affinity and insulin with low affinity, whereas the insulin receptor binds insulin with high affinity and IGF-1 with lower affinity. The similar concentrationdependent vasorelaxing effect of insulin and IGF-1 on epicardial vessels therefore suggests that each of the 2 peptides and bumetanide. Commission of Ontario. According to the Liquor Licence Act, anyone who wants to sell or serve beverage alcohol at an event or location other than a licensed establishment or a private residence must apply for a Special Occasion Permit. A MAP complements a Special Occasion Permit by specifying how, where and when alcohol may be served on municipal or city-owned property, the training required for those who serve alcohol and measures to prevent underage drinking and provide safe transportation of guests. The Centre for Addiction and Mental Health undertook a survey of municipalities in Ontario who have adopted these types of policies Gliksman et al., 1995 ; . The study found that those municipalities with comprehensive policies reported a greater reduction in alcohol-related problems such as vandalism, underage drinking and complaints to police. In Simcoe County Ontario, alcohol-related motor vehicle crashes are the leading cause of death for people aged 10 to 44 years. In addition, Simcoe County ranks higher than the provincial average in the percentage of current drinkers and binge drinkers. The goal of our initiative was to promote the development of municipal alcohol policies among municipalities in Simcoe County to prevent alcohol-related injuries!

Gold Coast City has some of the leading lifeguards in Australia - and it's official. Rob Dorrough, a full-time lifeguard at Surfers Paradise Beach, was named Lifeguard of the Year at the Australian Professional Ocean Lifeguard Association's recent conference in Sydney. And in a further tribute to the professionalism and dedication of Council's Lifeguard Service, education officer Sean Swain received the award for Outstanding Community Service. The Gold Coast has experienced some of the worst ever surfing conditions this summer. However, Chief Lifeguard, Warren Young, has attributed much of the safe season on Surfers Paradise Beach to the leadership and dedication of Mr Dorrough, who has been a part of Council's team of lifeguards for more than 17 years. The awards also provide an opportunity to recognise the work of all the men and women of Council's Lifeguard Service who work hard year-round to make the Left: Robert Dorrough - Lifeguard of the Year consistent dedicaton and innovation ; On the right: Sean Swain Gold Coast's beautiful beaches safe for - Outstanding Community Service an individual or community organisation for outstanding contribution s to beach water safety ; locals and visitors. Proteinuria at base line a urinary protein: creatinine ratio of less than 3 ; , 19 had a decrease in the urinary protein: creatinine ratio of at least 50 percent; the decrease was accompanied by an improvement in the base-line serum creatinine level in 5 patients and by a stable serum creatinine level in 14 patients. The mean arterial pressure; hematocrit; levels of blood urea nitrogen, serum creatinine, serum albumin, and complement C3 and C4; ANA titer; anti-dsDNA titer; urinary sediment; and urinary protein: creatinine ratio improved significantly with induction therapy in all patients P 0.001 ; . Table 2 shows the doses of immunosuppressants and corticosteroids received during maintenance therapy. Six patients with persistent nephrotic proteinuria after induction therapy had a remission during maintenance therapy three in the azathioprine group and three in the mycophenolate mofetil group ; . The mean dose of intravenous cyclophosphamide and of azathioprine was similar from visit to visit. The median dose of mycophenolate mofetil was 1500 mg per day during the first 12 months and subsequently decreased. The maintenance dose of mycophenolate mofetil was decreased to minimize gastrointestinal side effects and leukopenia in patients who had a sustained remission after a minimum of 12 months of therapy. Overall, during maintenance therapy, the mean dose of prednisone was significantly higher in the cyclophosphamide group 0.210.15 mg per day ; than in the mycophenolate mofetil group 0.12 0.13 mg per day, P 0.002 ; or the azathioprine group 0.15 0.14 mg per day, P 0.01 ; . The amount of corticosteroids used during maintenance therapy was determined on the basis of relapses and buspirone. Thrombocytopenia the most common hematologic toxicity associated with bortezomib therapy is transient thrombocytopenia , which returns toward baseline in the rest period between treatment cycles fig 4 and bortezomib.
Start date of comment period 06 14 2004 end date of comment period 07 28 2004 start date of notice period 07 11 2007 revision history number 6 revision history explanation revision #6: reasons - under the indications section, effective for dates of service on or after 12 08 2006 added an off-label use for bortezomib as a first-line treatment for multiple myeloma and busulfan.

CDDO-Im bortezomib; cytosolic extracts were then prepared and subjected to immunoblot analysis with anti-Smac or anti cyto-c Abs. As seen in Figure 6C upper and middle panels ; , treatment of MM.1S cells with CDDO-Im bortezomib triggers the release of both Smac and cyto-c. In contrast, neither agent alone.
Caffeine apparently antagonizes creatine's ergogenic effects, leading to a complete loss of creatine's benefits on intense intermittent exercise performance79, 80. Safety during pregnancy, lactation and or childhood: Unknown and butorphanol!

Bortezomib pills